Nisa Investment Advisors LLC Has $3.01 Million Holdings in Illumina, Inc. (ILMN)
Nisa Investment Advisors LLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 13,790 shares of the life sciences company’s stock after purchasing an additional 500 shares during the period. Nisa Investment Advisors LLC’s holdings in Illumina were worth $3,013,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Intellectus Partners LLC lifted its position in Illumina by 6.6% during the 2nd quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock worth $1,871,000 after buying an additional 664 shares in the last quarter. Axiom International Investors LLC DE lifted its position in Illumina by 60.9% during the 3rd quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock worth $37,142,000 after buying an additional 70,572 shares in the last quarter. Virtu Financial LLC bought a new stake in Illumina during the 3rd quarter worth about $577,000. Janus Henderson Group PLC lifted its position in Illumina by 1,556.2% during the 2nd quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock worth $57,263,000 after buying an additional 310,084 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in Illumina by 4.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 508,368 shares of the life sciences company’s stock worth $101,267,000 after buying an additional 23,647 shares in the last quarter. 91.60% of the stock is currently owned by hedge funds and other institutional investors.
ILMN has been the topic of several analyst reports. Citigroup boosted their price target on shares of Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 25th. Robert W. Baird raised shares of Illumina from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $184.00 to $228.00 in a research report on Wednesday, October 25th. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. Barclays boosted their price target on shares of Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 25th. Finally, BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $220.13.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at $241.31 on Friday. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. The stock has a market cap of $35,230.00, a PE ratio of 45.53, a PEG ratio of 3.25 and a beta of 0.79. Illumina, Inc. has a fifty-two week low of $156.50 and a fifty-two week high of $248.97.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. Illumina’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.97 EPS. analysts predict that Illumina, Inc. will post 3.76 earnings per share for the current year.
In other Illumina news, Director Robert S. Epstein sold 1,250 shares of the stock in a transaction dated Saturday, December 29th. The shares were sold at an average price of $217.38, for a total value of $271,725.00. Following the transaction, the director now directly owns 8,838 shares of the company’s stock, valued at approximately $1,921,204.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $210.43, for a total transaction of $4,208,600.00. Following the completion of the transaction, the director now directly owns 539,176 shares in the company, valued at $113,458,805.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 154,671 shares of company stock worth $33,626,228. Insiders own 0.89% of the company’s stock.
WARNING: “Nisa Investment Advisors LLC Has $3.01 Million Holdings in Illumina, Inc. (ILMN)” was published by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/01/19/nisa-investment-advisors-llc-has-3-01-million-holdings-in-illumina-inc-ilmn.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.